F.A. Eskens
Department of Medical Oncology
Rotterdam Cancer Institute (Daniel den Hoed Kliniek)
Netherlands
Name/email consistency: high
- Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. Eskens, F.A., Awada, A., Cutler, D.L., de Jonge, M.J., Luyten, G.P., Faber, M.N., Statkevich, P., Sparreboom, A., Verweij, J., Hanauske, A.R., Piccart, M. J. Clin. Oncol. (2001)
- Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor. Eskens, F.A., Levitt, N.C., Sparreboom, A., Choi, L., Mather, R., Verweij, J., Harris, A.L. Clin. Cancer Res. (2000)
- Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design. Eskens, F.A., Verweij, J. Crit. Rev. Oncol. Hematol. (2000)
- Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Eskens, F.A., Greim, G.A., van Zuylen, C., Wolff, I., Denis, L.J., Planting, A.S., Muskiet, F.A., Wanders, J., Barbet, N.C., Choi, L., Capdeville, R., Verweij, J., Hanauske, A.R., Bruntsch, U. Clin. Cancer Res. (2000)
- Farnesyl transferase inhibitors: current developments and future perspectives. Eskens, F.A., Stoter, G., Verweij, J. Cancer Treat. Rev. (2000)
